Streetbeat News

Price Targets

XPER

Rosenblatt analyst Steven Frankel has reiterated a Buy rating on Xperi (NYSE:XPER) and maintained a $15 price target for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

November 14, 2023 | 12:19 pm

AUMN

HC Wainwright & Co. analyst Heiko Ihle has maintained a Buy rating on Golden Minerals (AMEX:AUMN) but has reduced the price target from $9 to $3.1.

Portfolio Pulse from Benzinga Newsdesk

November 14, 2023 | 12:18 pm

BWEN

HC Wainwright & Co. analyst Amit Dayal has maintained a Buy rating on Broadwind (NASDAQ:BWEN) but has reduced the price target from $12 to $8.

Portfolio Pulse from Benzinga Newsdesk

November 14, 2023 | 12:14 pm

OCUP

HC Wainwright & Co. analyst Matthew Caufield has reiterated a Buy rating on Ocuphire Pharma (NASDAQ:OCUP) and maintained a $20 price target on the stock.

Portfolio Pulse from Benzinga Newsdesk

November 14, 2023 | 12:13 pm

UBX

HC Wainwright & Co. analyst Matthew Caufield has reiterated a Buy rating on Unity Biotechnology (NASDAQ:UBX) and maintained a price target of $10. This reaffirmation of the company's stock rating and price target suggests continued confidence in Unity Biotechnology's potential.

Portfolio Pulse from Benzinga Newsdesk

November 14, 2023 | 12:11 pm

STRO

HC Wainwright & Co. analyst Andrew Fein has reiterated a Buy rating on Sutro Biopharma (NASDAQ:STRO) and maintained a $16 price target for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

November 14, 2023 | 12:02 pm

GENI

Genius Sports (NYSE:GENI) has received 4 analyst ratings in the past quarter, with 1 bullish and 3 somewhat bullish. No indifferent, somewhat bearish, or bearish ratings were given. The average 12-month price target for GENI is $8.75, with a high of $9.00 and a low of $8.00, representing a 12.5% decrease from the previous target of $10.00. Analysts rate stocks based on future earnings potential and company risk profile, typically updating their ratings quarterly or after significant company events.

Portfolio Pulse from Benzinga Insights

November 14, 2023 | 12:00 pm

MOS

Over the past 3 months, 6 analysts have published their opinions on Mosaic (NYSE:MOS), with 1 bullish, 1 somewhat bullish, and 4 indifferent ratings. The average 12-month price target for Mosaic is $39.83, with a high of $48.00 and a low of $35.00, representing a 2.85% decrease from the previous target of $41.00.

Portfolio Pulse from Benzinga Insights

November 14, 2023 | 12:00 pm

SKIN

Beauty Health (NASDAQ:SKIN) has received mixed analyst ratings in the last quarter with 2 bullish, 1 indifferent, and 1 somewhat bearish rating. The average 12-month price target among 4 analysts is $9.38, with a high of $23.00 and a low of $2.00. This target is a 14.73% decrease from the previous target of $11.00. Analyst ratings are opinions based on financial analysis and are updated quarterly.

Portfolio Pulse from Benzinga Insights

November 14, 2023 | 12:00 pm

RGF

The Real Good Food (NASDAQ:RGF) has received 4 bullish analyst ratings in the last quarter, with no neutral or bearish ratings. The average 12-month price target among these analysts is $7.5, with a high of $10.00 and a low of $4.00, representing a 25.0% decrease from the previous average price target of $10.00.

Portfolio Pulse from Benzinga Insights

November 14, 2023 | 12:00 pm